Endocyte Inc

General

Total Cases2

Active Cases--

Patents43

CourtsS.D. Indiana

TypeOperating Company

Elite Ratings

--

independent-consultant

Ratings

Experience

Grade

Trend

DCT

--

--

--

PTAB

L1

C

CAFC

--

--

--

Analytics

Cases

Litigated Patents

Ratings Trends

Recent Dockets

Entered	Case	Description
10/02/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	ORDER granting [45] Motion to Stay - Defendants' motion for stay of litigation pending decision on Defendants' Rule 12(b)(1) and 12(b)(6) motion to dismiss is granted. [Filing No. [45] .] In accordance with Plaintiffs' alternate request, the Court requires Defendants to provide regularly scheduled updates on the status of PNT2002's approval process to ensure that Plaintiffs have reasonable notice of the imminence of Defendants' commercial launch. (See Order For Additional Details.) Signed by Magistrate Judge Tim A. Baker on 10/02/2024. (AJG) (Entered: 10/02/2024) ORDER granting [45] Motion to Stay - Defendants' motion for stay of litigation pending decision on Defendants' Rule 12(b)(1) and 12(b)(6) motion to dismiss is granted. [Filing No. [45] .] In accordance with Plaintiffs' alternate request, the Court requires Defendants to provide regularly scheduled updates on the status of PNT2002's approval process to ensure that Plaintiffs have reasonable notice of the imminence of Defendants' commercial launch. (See Order For Additional Details.) Signed by Magistrate Judge Tim A. Baker on 10/02/2024. (AJG) (Entered: 10/02/2024)
09/24/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	DECLARATION of William A. McKenna re [55] Reply in Support of Motion by ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (Attachments: # [1] Exhibit 1-Study Details - Clinical Trials, # [2] Exhibit 2-Emaill Correspondence)(McKenna, William) (Entered: 09/24/2024)
09/24/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	REPLY in Support of Motion re [45] MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36) , filed by Defendants ELI LILLY AND CO., POINT BIOPHARMA GLOBAL INC., POINT BIOPHARMA INC.. (McKenna, William) (Entered: 09/24/2024)
09/17/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	RESPONSE in Opposition re [45] MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36) [Plaintiffs' Response In Opposition To Defendants' Motion To Stay Discovery], filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # [1] Exhibit 1 - Lantheus Press Release, # [2] Exhibit 2 - PNT2002 ESMO Abstract)(Hidde, Kandi) (Entered: 09/17/2024) RESPONSE in Opposition re [45] MOTION to Stay of Litigation Pending Decision on Defendants' Rule 12(b)(1) and 12(b)(6) Motion to Dismiss (ECF Nos. 35-36) [Plaintiffs' Response In Opposition To Defendants' Motion To Stay Discovery], filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # [1] Exhibit 1 - Lantheus Press Release, # [2] Exhibit 2 - PNT2002 ESMO Abstract)(Hidde, Kandi) (Entered: 09/17/2024)
09/06/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	ORDER granting [49] Motion to Appear pro hac vice. Attorney Max Accardi for ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION added. Signed by Magistrate Judge Tim A. Baker on 9/6/2024. (KAA) (Entered: 09/06/2024)
09/06/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	ORDER granting [48] Motion to Appear pro hac vice. Attorney Christie Corn for ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION added. Signed by Magistrate Judge Tim A. Baker on 9/6/2024. (KAA) (Entered: 09/06/2024)
09/06/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	ORDER ON SEPTEMBER 6, 2024, TELEPHONIC INITIAL PRETRIAL CONFERENCE - Plaintiffs appeared in person and by counsel and Defendants appeared by counsel September 6, 2024, for a telephonic initial pretrial conference. The Court addressed issues regarding case management and settlement. Given the disagreements in the proposed Case Management Plan [Filing No. 42], as well as Defendants' motion to stay [Filing No. 45] (which is not yet ripe), the Court denied the proposed CMP. The Court will rule on Defendants' motion to stay promptly after that motion is fully briefed. If that motion is denied, the Court will order counsel to file a revised, proposed CMP. Signed by Magistrate Judge Tim A. Baker. (MGL) (Entered: 09/06/2024) ORDER ON SEPTEMBER 6, 2024, TELEPHONIC INITIAL PRETRIAL CONFERENCE - Plaintiffs appeared in person and by counsel and Defendants appeared by counsel September 6, 2024, for a telephonic initial pretrial conference. The Court addressed issues regarding case management and settlement. Given the disagreements in the proposed Case Management Plan [Filing No. 42], as well as Defendants' motion to stay [Filing No. 45] (which is not yet ripe), the Court denied the proposed CMP. The Court will rule on Defendants' motion to stay promptly after that motion is fully briefed. If that motion is denied, the Court will order counsel to file a revised, proposed CMP. Signed by Magistrate Judge Tim A. Baker. (MGL) (Entered: 09/06/2024)
09/06/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	ORDER granting [47] Motion to participate in initial pretrial conference. The representatives for the Plaintiffs identified in Paragraph 4 of the Motion are allowed to participate in the initial pretrial conference. Counsel for Plaintiffs shall provide the call-in information to said representatives. (MGL) (Entered: 09/06/2024)
09/05/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	MOTION for Attorney(s) Max C. Accardi to Appear pro hac vice (Filing fee $100, receipt number AINSDC-8323260), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # [1] Text of Proposed Order Proposed Order)(Accardi, Max) (Entered: 09/05/2024)
09/05/24	Endocyte Inc v. Point Biopharma Global Inc 1:24-CV-01011 ( S.D. IN )	First MOTION for Attorney(s) Christie K. Corn to Appear pro hac vice (Filing fee $100, receipt number BINSDC-8323083), filed by Plaintiffs ENDOCYTE, INC., NOVARTIS PHARMACEUTICAL CORPORATION, PURDUE RESEARCH FOUNDATION. (Attachments: # [1] Text of Proposed Order)(Corn, Christie) (Entered: 09/05/2024)